Under the threat of lawsuits, seven major commercial insurers doing business in New York will now cover direct acting antivirals for patients with HCV infection, as will NY's Medicaid program. The plans will also stop denying coverage to patients who abuse drugs or alcohol.
The US Food and Drug Administration approved a supplemental New Drug Application submitted by drug maker AbbVie for Viekira Pak without ribavirin to treat patients with chronic hepatitis C genotype 1b and compensated cirrhosis.
Patients with hepatitis C were two to five times more likely to develop some types of head and neck cancers, according to a study conducted by the University of Texas MD Anderson Cancer Center in Houston.
Work being done to treat and cure hepatitis C today could make it almost a non-issue for future generations, thanks to groups like the World Health Organization (WHO) and others putting the focus on parts of the world that need help in this area the most.